Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Lincoff

Showing results (61-70 of 116) with videos related to

Pageof 12
Sort By:
Circulation|November 11, 1999
Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary interventionS R Steinhubl, K Kottke-Marchant, D J Moliterno, et al.
American Heart Journal|January 30, 1999
Is all unstable angina the same? insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). The CAVEAT-InvestigatorsR A Harrington, R M Califf, D R Holmes, et al.
Bulletin of Mathematical Biology|January 1, 1990
Experimental determination and mathematical model of the transient incorporation of cholesterol in the arterial wallS J Neumann, S A Berceli, E M Sevick, et al.
American Heart Journal|June 30, 2000
Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockadeD J Kereiakes, S D Berkowitz, A M Lincoff, et al.
The American Journal of Cardiology|December 15, 1995
Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary interventionR A Harrington, N S Kleiman, K Kottke-Marchant, et al.
Circulation Research|December 1, 1993
Differences in cardioprotective efficacy of adrenergic receptor antagonists and Ca2+ channel antagonists in an animal model of dilated cardiomyopathy. Effects on gross morphology, global cardiac function, and twitch forceM G Glass, F Fuleihan, R Liao, et al.
American Heart Journal|October 1, 1990
Successful coronary angioplasty in two patients with cardiogenic shock using the Nimbus Hemopump support deviceA M Lincoff, J J Popma, E R Bates, et al.
JAMA|July 4, 2001
Risk of stroke associated with abciximab among patients undergoing percutaneous coronary interventionK M Akkerhuis, J W Deckers, A M Lincoff, et al.
Journal of the American College of Cardiology|August 10, 2000
Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for StentL Cho, E J Topol, C Balog, et al.
Circulation|July 12, 2001
Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularizationA M Lincoff, D J Kereiakes, M A Mascelli, et al.
Pageof 12

Showing results (61-70 of 116) with videos related to

Sort By:
Pageof 12
Circulation|November 11, 1999
Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary interventionS R Steinhubl, K Kottke-Marchant, D J Moliterno, et al.
American Heart Journal|January 30, 1999
Is all unstable angina the same? insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). The CAVEAT-InvestigatorsR A Harrington, R M Califf, D R Holmes, et al.
Bulletin of Mathematical Biology|January 1, 1990
Experimental determination and mathematical model of the transient incorporation of cholesterol in the arterial wallS J Neumann, S A Berceli, E M Sevick, et al.
American Heart Journal|June 30, 2000
Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockadeD J Kereiakes, S D Berkowitz, A M Lincoff, et al.
The American Journal of Cardiology|December 15, 1995
Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary interventionR A Harrington, N S Kleiman, K Kottke-Marchant, et al.
Circulation Research|December 1, 1993
Differences in cardioprotective efficacy of adrenergic receptor antagonists and Ca2+ channel antagonists in an animal model of dilated cardiomyopathy. Effects on gross morphology, global cardiac function, and twitch forceM G Glass, F Fuleihan, R Liao, et al.
American Heart Journal|October 1, 1990
Successful coronary angioplasty in two patients with cardiogenic shock using the Nimbus Hemopump support deviceA M Lincoff, J J Popma, E R Bates, et al.
JAMA|July 4, 2001
Risk of stroke associated with abciximab among patients undergoing percutaneous coronary interventionK M Akkerhuis, J W Deckers, A M Lincoff, et al.
Journal of the American College of Cardiology|August 10, 2000
Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for StentL Cho, E J Topol, C Balog, et al.
Circulation|July 12, 2001
Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularizationA M Lincoff, D J Kereiakes, M A Mascelli, et al.
Pageof 12